BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 19, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

SF1126: Updated Phase I data

Updated data from 33 evaluable patients in an ongoing, open-label, dose-escalation, U.S. Phase I trial showed that twice-weekly SF1126 produced 19 cases of stable disease with a median duration of 13 weeks. The MTD has not been reached at doses of up to 1,110...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >